

ALEXION PHARMACEUTICALS INC
 Form 4
 July 27, 2007

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL
 OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 SQUINTO STEPHEN P

2. Issuer Name and Ticker or Trading Symbol
 ALEXION PHARMACEUTICALS INC [ALXN]

5. Relationship of Reporting Person(s) to Issuer
 (Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)
 07/25/2007

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)
 EVP & Head of Research

C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE
 (Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 ___ Form filed by More than One Reporting Person

CHESHIRE, CT 06410

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Ownership (Instr. 4) |
|---|--------------------------------------|--|--------------------------------|---|---|--|--|
| | | | | (A) or (D) | Price | | |
| Common Stock, par value \$.0001 per share | 07/25/2007 | | M | 8,750 | A \$ 9 | 33,764 | D |
| Common Stock, par value \$.0001 per share | 07/25/2007 | | M | 8,750 | A \$ 9.5 | 42,514 | D |

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 4

| | | | | | | | |
|---|------------|---|----------------------|---|-------------|--------|---|
| Common Stock, par value \$.0001 per share | 07/25/2007 | M | 5,249 | A | \$ 10.74 | 47,763 | D |
| Common Stock, par value \$.0001 per share | 07/25/2007 | M | 2,251 | A | \$ 10.74 | 45,512 | D |
| Common Stock, par value \$.0001 per share | 07/25/2007 | S | <u>4,516</u> (1) | D | \$ 56.9 | 40,996 | D |
| Common Stock, par value \$.0001 per share | 07/25/2007 | S | <u>20,484</u> (1) | D | \$ 56.5 | 20,512 | D |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Amount or Number of Shares | |
|---|--|---|---|--------------------------------------|---|--|---|---|-------|
| | | | | Code | V (A) (D) | Date Exercisable | Expiration Date | Title | |
| Option to Purchase Common Stock | \$ 9 | 07/25/2007 | | M | 8,750 | 12/04/1998 | 12/04/2008 | Common Stock, par value \$.0001 per share | 8,750 |
| | \$ 9.5 | 07/25/2007 | | M | 8,750 | 07/27/1999 | 07/27/2009 | | 8,750 |

| | | | | | | | | | |
|---------------------------------|----------|------------|---|-------|------------|------------|--|--|-------|
| Option to Purchase Common Stock | | | | | | | | Common Stock, par value \$.0001 per share | |
| Option to Purchase Common Stock | \$ 10.74 | 07/25/2007 | M | 5,249 | 03/04/2003 | 03/04/2013 | | Common Stock, par value \$.0001 per share | 5,249 |
| Option to Purchase Common Stock | \$ 10.74 | 07/25/2007 | M | 2,251 | 03/04/2003 | 03/04/2013 | | Common Stock, par value \$.0001 per share | 2,251 |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|---|---------------|-----------|------------------------|-------|
| | Director | 10% Owner | Officer | Other |
| SQUINTO STEPHEN P C/O ALEXION PHARMACEUTICALS INC 352 KNOTTER DRIVE CHESHIRE, CT 06410 | | | EVP & Head of Research | |

Signatures

/s/ Stephen Squinto 07/27/2007

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported by this Form 4 are made pursuant to the terms of a Sales Plan designed to meet the requirements of Rule 10b5-1 (c) (1) of The Securities Exchange Act.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.